Guillaume Mathey

23PUBLICATIONS
87CO-AUTHORS
Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological methodsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Sep 26, 2026
Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.

|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

|May 05, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

|Sep 04, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.

Antoine Gavoille, Mikail Nourredine, Fabien Rollot

|Aug 25, 2025
Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.

Guillaume Mathey, Jonathan Epstein, Tom Alix

|Jul 30, 2025
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Antoine Gavoille, Emmanuelle Leray, Romain Marignier

Pageof 4

Frequent Collaborators

10 joint publications

Jean-Philippe Camdessanché

9 joint publications

Jonathan Ciron

9 joint publications

Elisabeth Maillart

8 joint publications

Caroline Papeix